Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
11 Luglio 2024 - 3:00PM
Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing
and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today
announced that they have entered into an agreement to cross-license
patent estates covering tumor-informed approaches to detect minimal
residual disease (MRD). The agreement helps solidify each company’s
freedom to operate in the MRD market and broadens patient access to
the benefits of MRD testing.
MRD tests are blood-based diagnostic tools that enable
clinicians to monitor therapeutic responses to cancer treatment
more closely than with traditional cancer detection technologies,
such as imaging, and detect cancer recurrence earlier. While the
utilization of MRD testing is nascent, the adoption rate is growing
quickly, and the market size is expected to mature to $20 billion
over the next several years.
Personalis and Myriad are each pioneering tumor-informed,
genome-scale approaches to power ultra-sensitive MRD tests,
enabling earlier cancer recurrence detection and more refined
therapy monitoring than alternative approaches. Both companies
value tumor-informed approaches for cancer patients and have
developed deep, foundational patent estates in the field, and each
sees the benefits of an ultra-sensitive approach as key to making
MRD testing the standard of care.
“Myriad and Personalis are each working to re-define the
standard for MRD testing and increasing market access to better
inform clinical decision making for the treatment and monitoring of
oncology patients,” said Paul J. Diaz, President and CEO, Myriad
Genetics. “We believe that our unique sets of capabilities and
inclusive approach to using intellectual property for the benefit
of patients will help drive broader MRD testing adoption,
reimbursement, and greatly advance this opportunity for patients in
this emerging and under-penetrated market. Myriad’s Precise MRD is
a tumor-informed, genome-scale MRD test that is part of Precise
Oncology Solutions, our expanding portfolio of comprehensive
molecular diagnostic tools for oncology detection and
treatment.”
“Personalis has presented compelling clinical evidence across
large lung cancer, breast cancer, and immunotherapy cohorts
demonstrating the ability of its NeXT Personal® whole-genome-based
MRD platform to drive a leap in performance for patients,” said
Chris Hall, CEO of Personalis. “We are excited to deepen our
collaboration with Myriad by recognizing the importance of our
respective patent estates in the field.”
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad Genetics develops
and offers genetic tests that help assess the risk of developing
disease or disease progression and guide treatment decisions across
medical specialties where genetic insights can significantly
improve patient care and lower healthcare costs. For more
information, visit www.myriad.com.
About Personalis, Inc.At Personalis,
we are transforming the active management of cancer through
breakthrough personalized testing. We aim to drive a new paradigm
for cancer management, guiding care from biopsy through the life of
the patient. Our highly sensitive assays combine tumor-and-normal
profiling with proprietary algorithms to deliver advanced insights
even as cancer evolves over time. Our products are designed to
detect MRD and recurrence at the earliest time points, enable the
selection of targeted therapies based on ultra-comprehensive
genomic profiling, and enhance biomarker strategy for drug
development. Personalis is based in Fremont,
California. To learn more, visit www.personalis.com and
connect with us on LinkedIn and X (Twitter).
Myriad Genetics Forward-Looking StatementsThis
press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to the expected benefits of Myriad’s
collaboration with Personalis, Myriad’s freedom to operate in the
MRD market, the expected adoption rate and size of the market for
MRD testing, Myriad’s expanding portfolio of comprehensive
molecular diagnostic tools for oncology detection and treatment,
and the belief that the companies’ unique sets of capabilities and
inclusive approach to using intellectual property will help drive
MRD testing adoption and reimbursement, broadening patient access
to the benefits of MRD testing in the future. These
“forward-looking statements” are management’s expectations of
future events as of the date hereof and are subject to known and
unknown risks and uncertainties that could cause actual results,
conditions, and events to differ materially and adversely from
those anticipated, including the risks, uncertainties and other
factors that relate to Myriad’s and Personalis’ prosecution and
defense of their respective MRD patent estates, the development and
clinical effectiveness of Myriad’s Precise MRD test, and the
adoption and use of Myriad’s Precise MRD test by oncologists. Such
factors also include those risks described in Myriad’s filings with
the U.S. Securities and Exchange Commission (SEC), including
Myriad’s Annual Report on Form 10-K filed on February 28, 2024, and
its Quarterly Report on Form 10-Q filed on May 8, 2024, as well as
any updates to those risk factors filed from time to time in
Myriad’s Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. Myriad is not under any obligation, and it expressly disclaims
any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise
except as required by law.
Personalis Forward-Looking StatementsThis press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All
statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to the expected benefits of
Personalis’ collaboration with Myriad, Personalis’ freedom to
operate in the MRD market, the expected adoption rate and size of
the market for MRD testing, the attributes, advantages, sensitivity
or clinical relevance of the NeXT Personal platform, and the belief
that the companies’ unique sets of capabilities and inclusive
approach to using intellectual property will help drive MRD testing
adoption and reimbursement, broadening patient access to the
benefits of MRD testing in the future. Such forward-looking
statements involve known and unknown risks and uncertainties and
other factors that may cause actual results to differ materially
from any anticipated results or expectations expressed or implied
by such statements, including the risks, uncertainties and other
factors that relate to Personalis’ and Myriad’s prosecution and
defense of their respective MRD patent estates, Personalis’ ability
to demonstrate attributes, advantages, sensitivity or clinical
relevance of the NeXT Personal platform and the adoption and use of
the NeXT Personal platform by oncologists. These and other
potential risks and uncertainties that could cause actual results
to differ materially from the results predicted in these
forward-looking statements are described under the captions “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” in Personalis’ Annual Report
on Form 10-K for the year ended December 31, 2023, filed with the
SEC on February 28, 2024, and its Quarterly Report on Form 10-Q for
the quarter ended March 31, 2024, filed with the SEC on May 8,
2024. All information provided in this release is as of the date of
this press release, and any forward-looking statements contained
herein are based on assumptions that we believe to be reasonable as
of this date. Undue reliance should not be placed on the
forward-looking statements in this press release, which are based
on information available to Personalis on the date hereof.
Personalis undertakes no duty to update this information unless
required by law.
Investors: Caroline
Cornerinvestors@personalis.com415-202-5678
Matt Scalo(801) 584-3532IR@myriad.com
Media: pr@personalis.com
Glenn Farrell(385) 318-3718PR@myriad.com
Grafico Azioni Personalis (NASDAQ:PSNL)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Personalis (NASDAQ:PSNL)
Storico
Da Dic 2023 a Dic 2024